Adverum Biotechnologies, Inc. (ADVM) Stock: Why It’s Up


Adverum Biotechnologies, Inc. (ADVM) is making a move up in the market today. The company, one that is focused on the biotechnology industry, is currently priced at $12.04 after a move up of 6.08% so far today. When it comes to biotechnology companies, there are quite a few factors that have the ability to lead to movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines surrounding ADVM:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-04-19 04:01PM Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Society 2019 Annual Meeting
08:58AM The Keys to Successfully Timing the Markets – September 04, 2019
Aug-28-19 04:01PM Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October
Aug-27-19 11:36AM Is the Options Market Predicting a Spike in Adverum Biotechnologies (ADVM) Stock?
Aug-16-19 11:23AM What’s in Store for Aytu BioScience’s (AYTU) Q4 Earnings?

However, when making an investing decision, prospective investors should take a look at far more than news, especially in the generally speculative biotech sector. Here’s what’s going on with Adverum Biotechnologies, Inc..

Returns That ADVM Investors Have Seen

Although a move up on a single session, like the move that we’re seeing from Adverum Biotechnologies, Inc. might lead to excitement in some investors, a single session gain by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always a good idea to look into trends just a single session. In the case of ADVM, here are the movements that investors have seen:

  • Past 5 Sessions – In the last seven days, ADVM has produced a change in value in the amount of 12.84%.
  • Past Month – The monthly returns from Adverum Biotechnologies, Inc. has been 0.33%.
  • Quarterly – In the past three months, the stock has generated a ROI that comes to 12.31%
  • Past 6 Months – Over the last six months, we have seen a performance that amounts to 151.88% from the company.
  • Year To Date – Since the open of this year ADVM has produced a ROI of 282.22%.
  • Annually – Finally, over the past year, we have seen performance in the amount of 72.00% out of ADVM. Over this period of time, the stock has traded at a high of -26.51% and a low price of 359.54%.

Ratios To Watch

Looking at a few ratios having to do with a company generally gives traders a view of just how risky and/or rewarding a an investment option might be. Here are some of the most important ratios to think about when digging into ADVM.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the short ratio climbs, it means that more investors have a belief that the stock is going to tumble. Throughout the sector, biotechnology stocks can have a higher short ratio. However, we tend to see quite a few short squeezes in the industry. Nonetheless, with regard to Adverum Biotechnologies, Inc., the stock’s short ratio amounts to 8.58.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Essentially, they measure the company’s abilities to pay its debts as they mature using current assets or quick assets. Because many biotech several companies rely heavily on continued investor support, the current and quick ratios can seem damning. Nonetheless, several better companies in the biotech space do have good quick and current ratios. As it relates to ADVM, the quick and current ratios add up to 17.80 and 17.80 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets owned by the company. In this case, that ratio comes in at 2.79.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is an important ratio to consider. In the case of ADVM, the cash to share value ratio works out to 2.61.

How Analysts Feel About Adverum Biotechnologies, Inc.

Although it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to use their opinions when validating your own opinions before making investment decisions in the biotech industry. Below you’ll find the recent moves that we have seen from analysts when it comes to ADVM.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-14-19 Resumed Raymond James Mkt Perform
Nov-02-18 Downgrade SunTrust Buy → Hold
Nov-02-18 Downgrade Raymond James Outperform → Mkt Perform
Sep-21-18 Initiated Cantor Fitzgerald Overweight
Aug-30-18 Initiated SunTrust Buy $11

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ADVM, here’s what we’re seeing:

Institutions own 85.50% of the company. Institutional interest has moved by 14.72% over the past three months. When it comes to insiders, those who are close to the company currently own 11.22% percent of ADVM shares. Institutions have seen ownership changes of an accumulative 0.26% over the last three months.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 68.02M shares of Adverum Biotechnologies, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ADVM has a float of 56.21M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ADVM, the short percent of the float is 16.56%.


What have ween seen from ADVM in terms of financial results?Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts are expecting that Adverum Biotechnologies, Inc. will come up with earnings per diluted share that comes to -1.13, with -0.26 being announced in the earnings announcement for the current quarter. Although this isn’t associated with earnings, since we are talking on the topic of analysts, Adverum Biotechnologies, Inc. is presently rated a 2.60 considering a scale that ranges from 1 to 5 on which 1 is the poorest possible Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – In the last 5 years, Adverum Biotechnologies, Inc. has generated a movement in sales that works out to be 27.40%. EPS in the last 5 years have generated a change of -36.80%.
  • Q/Q – In terms of quarter over quarter data, or Q/Q data as it is generally referred to as in the human world, ADVM has experienced a change in earnings that amounts to 22.20%. Adverum Biotechnologies, Inc. has also seen a change when it comes to sales that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m heavily dependent on human beings. After all, humans built me! Even though my creators enabled me to learn on my own, it’s far easier to do so through the receipt of human feedback. At the bottom of this content, you’ll find a section for comments. If you would like for me consider other data, tweak the way in which I communicate, comprehend information from a different perspective, or if you’d like to tell me anything else, I’d love to learn. To let me in on your thoughts take a moment to leave a comment below. I will read that comment and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here